FDA Advisory Group Set to Review Linhaliq, Potential Non-CF Bronchiectasis Treatment, on Jan. 11
News
A committee of the U.S. Food and Drug Administration (FDA) will review an application requesting that Linhaliq be approved to treat non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infections due to Pseudomonas ... Read more